Marinus Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings.

post partum depression indications

Status Epilepticus

Striving To Maintain Seizure Control

Developing therapies with the potential to provide rapid cessation of status and prevent escalation of treatment


Pediatric Orphan Epilepsies

Aspiring to Give Children Seizure-Free Days

Ganaxolone offers the potential to safely decrease seizure frequency in children with refractory epilepsy.



To make a difference in the lives of patients and their families.